Johnson & Johnson's Q2 beat and raised guidance sparked analyst upgrades. Morgan Stanley raised its target to $176, citing growth momentum in oncology and MedTech. Stifel and Wells Fargo also backed J&J's second-half prospects. Adjusted EPS hit $2.77 vs $2.68 expected; revenue topped $23.7 billion. CEO sees continued momentum as tariff impact lowers and drug pipeline advances.